Abstracts tagged "IgG4 Related Disease"

Abstract Number: 1835 • ACR Convergence 2024
FoxP3Hi CTLA4+ ICOS+ Regulatory T Cells Are Expanded in Patients with Sarcoidosis but Not Systemic Sclerosis or IgG4-Related Disease
Laura Yockey¹, Thomas Guy², Chinmay Gadiraju³, Ian Doyle¹, Jesse Akaa⁴, Alison Puri⁵, Zachary Wallace⁶, Guy Katz¹, Sydney Montesi¹, John Stone⁷, Flavia Castelino¹, Shiv Pillai⁸, Andrew Luster⁹, Vinay Mahajan³ and Cory Perugino¹, ¹Massachusetts General Hospital, Boston, MA, ²Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Massachussets General Hospital, Boston, MA, ⁵Boston University, Brookline, MA, ⁶Massachusetts General Hospital, Newton, MA, ⁷Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁸Harvard Medical School, Cambridge, MA, ⁹Massachusetts General Hospital, Charlestown, MA
Background/Purpose: The absence of regulatory T cells (Tregs) results in multiorgan autoimmunity in the context of monogenic “Tregopathies”, but their role in mediating polygenic autoimmune…
Abstract Number: 2027 • ACR Convergence 2024
Clinical Features and Treatment of Retroperitoneal Fibrosis in a Referral Hospital and Literature Review
Adrián Martín-Gutiérrez¹, Javier Loricera², Fernando Lopez-Gutierrez³ and Ricardo Blanco-Alonso⁴, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Retroperitoneal fibrosis (RPF) is usually idiopathic (iRPF), but may be secondary to drugs, neoplasms, infections, or may be part of an IgG4-related disease. Our…
Abstract Number: 2031 • ACR Convergence 2024
A Contemporary Assessment of the Burden of Malignancy in IgG4-Related Disease
Grace McMahon¹, Isha Jha¹, Guy Katz¹, Cory Perugino¹, Ana Fernandes¹, John Stone² and Zachary Wallace³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital , Harvard Medical School, Concord, MA, ³Massachusetts General Hospital, Newton, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a fibro-inflammatory disorder that can affect nearly any organ. Because of the often tumefactive nature of IgG4-RD and its typical…
Abstract Number: 2035 • ACR Convergence 2024
Older Age and Higher Erythrocyte Sedimentation Rate Are Associated with Increased Disease Burden at Diagnosis in a Cohort of IgG4-Related Disease Patients
Humberto Campos Clemente, Barbara Bayeh, Monica Raquel de Souza Aquino, Fernanda Oliveira de Andrade Lopes, Thiago Quadrante Freitas, Rafael Alves Cordeiro and Henrique Ayres Mayrinki Giardini, Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil
Background/Purpose: Immunoglobulin G4-related disease (IgG4-RD) is a fibroinflammatory condition primarily affecting middle-aged males. It is characterized by mass lesions affecting various organs, such as the…
Abstract Number: 0007 • ACR Convergence 2024
Bromodomain 2 of BET Proteins Plays a Crucial Role in Follicular/peripheral Helper T Cell and Plasma Cell Differentiation
Ryota Sato¹, Mitsuhiro Akiyama², Koichi Oshita³, Yuko Kawano³, Yuki Imura³, Piruzyan Mariam⁴, Manami Kikuchi³, Mikako Murase³, Sachiko Mochiduki³, Naohiro Hashimoto³, Masayuki Watanabe³, Keiko Yoshimoto⁵, Tsutomu Takeuchi⁶, Kenji Chiba⁷ and Yuko Kaneko⁵, ¹Mitsubishi Tanabe Pharma Corporation, Brighton, MA, ²Keio University School of Medicine, Palo Alto, CA, ³Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan, ⁴Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan, ⁵Keio University School of Medicine, Tokyo, Japan, ⁶Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ⁷Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
Background/Purpose: Proteins motifs bromodomain 1 (BD1) and BD2 within the BET family proteins regulate gene expression of inflammatory cytokines and lymphocyte proliferation by binding to…
Abstract Number: 2037 • ACR Convergence 2024
Can Tofacitinib Be the Saviour in Treatment of Refractory IgG4-Related Disease : A Multicentre Experience from India
Jasneet Singh¹, SHRUTI BAJAD² and DHAVAL TANNA³, ¹THE MEDICLINIC-ARTHRITIS & RHEUMATOLOGY CENTER, LUDHIANA, Punjab, India, ²Moolchand hospital , Delhi, DELHI, Delhi, India, ³SAURASHTRA RHEUMATOLOGY CENTER, Rajkot, Gujarat, India
Background/Purpose: We did an observational study to assess the efficacy and safety of the Janus kinase (JAK) inhibitor tofacitinib in patients having refractory IgG4-Related Disease…
Abstract Number: 0285 • ACR Convergence 2024
Anti-THSD7A Antibodies Are Not Broadly Associated with IgG4-Related Disease or IgG4-Related Membranous Nephropathy
Guy Katz¹, Jesse Akaa², Grace McMahon¹, Isha Jha¹, Ian Doyle¹, Ana Fernandes¹, Zachary Wallace³, Shiv Pillai⁴, John Stone⁵ and Cory Perugino¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachussets General Hospital, Boston, MA, ³Massachusetts General Hospital, Newton, MA, ⁴Harvard Medical School, Cambridge, MA, ⁵Massachusetts General Hospital , Harvard Medical School, Concord, MA
Background/Purpose: Membranous nephropathy (MN) is a known manifestation of IgG4-related disease (IgG4-RD). Unlike primary MN, most patients with IgG4-related MN do not have anti-phospholipase 2…
Abstract Number: 2045 • ACR Convergence 2024
Descriptive Study on the Use of Serum Levels of Immunoglobulin G4, Immunoglobulin E and Eosinophil Count as Serum Biomarkers Across Four Clinical Phenotypes of IgG4-Related Disease
Vineetha Philip¹, Soudabeh Daliri², Alma Aveytia Camacho², Ruba Memon³, Myriam Guevara² and Sarah Kazzaz⁴, ¹Houston Methodist Hospital, Sugar Land, TX, ²Houston Methodist, Houston, TX, ³Houston Methodist, Missouri City, TX, ⁴Houston Methodist Hospital, Houston, TX
Background/Purpose: IgG4 – Related Disease (IgG4-RD) is a multisystem immune-mediated fibroinflammatory disorder that can affect nearly any organ and can mimic other inflammatory conditions, malignancy…
Abstract Number: 0286 • ACR Convergence 2024
Damage Associated with Disease-Specific Effects and Diagnostic or Therapeutic Procedures Is Highly Prevalent in IgG4-Related Disease
Guy Katz¹, Zachary Wallace², Cory Perugino¹, Grace McMahon¹, Isha Jha¹, Ana Fernandes¹ and John Stone³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Newton, MA, ³Massachusetts General Hospital , Harvard Medical School, Concord, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic immune-mediated disease that can affect nearly any organ or anatomic site. Although the disease responds well to glucocorticoids…
Abstract Number: 2051 • ACR Convergence 2024
Clinical Outcomes and Predictors of Relapse in Patients with IgG4-Related Disease Treated with Rituximab: A Real-World Experience
Guy Katz¹, Zachary Wallace², Grace McMahon¹, Isha Jha¹, Ana Fernandes¹, Bohang Jiang¹, Yuqing Zhang³, Hyon K. Choi⁴, Cory Perugino¹ and John Stone⁵, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Newton, MA, ³Massachusetts General Hospital, Quincy, MA, ⁴Massachusetts General Hospital, Lexington, MA, ⁵Massachusetts General Hospital , Harvard Medical School, Concord, MA
Background/Purpose: Rituximab (RTX) is often used to treat IgG4-related disease (IgG4-RD), but real-world data on clinical outcomes remain limited. Defining time to relapse and predictors…
Abstract Number: 0289 • ACR Convergence 2024
Effectiveness of Rituximab in IgG4 Related Disease
Fernando Lopez-Gutierrez¹, Javier Loricera², Cristina Hormigos³, Dalifer Freites Nuñez⁴, Maria Rodriguez-Laguna⁵, Patricia Moya Albarado⁶, Marta López I Gómez⁷, Hèctor Corominas⁸, Maite Silva-Díaz⁹, GUILLERMO GONZALEZ ARRIBAS⁹, Angel Garcia-Aparicio¹⁰, Judit Font Urgelles¹¹, Ivette Casafont-Sole¹¹, Pablo Martínez Calabuig¹², Elisabet Castaneda¹³, Carolina Merino¹⁴, Raquel Zas¹⁵, Juan Molina-Collada¹⁶, Rafael Benito Melero-Gonzalez¹⁷, Eva Galindez-Agirregoikoa¹⁸, Andrea Hernández-Martín¹⁹, Lucia Pantoja²⁰, Ignacio Brana Abascal²¹, Vega Jovani²², Elia Valls-Pascual²³, Natalia Mena Vázquez²⁴, Adela Gallego- Flores²⁵, Noelia Cabaleiro Raña²⁶, Raul Veroz²⁷, Mariano Andres²⁸, Santos Castañeda²⁹ and Ricardo Blanco-Alonso³⁰, and Rituximab in IgG4 Related Disease Spanish Cooperative Group, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Hospital Clínico San Carlos, Madrid, Madrid, Spain, ⁴Hospital Clínico San Carlos. Madrid. Spain., Madrid, Spain, ⁵Resident in Rheumatology, Madrid, Spain, ⁶Hospital de San Pau, Barcelona, Spain, ⁷Hospital Universitario Alava, Vitoria, Pais Vasco, Spain, ⁸Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁹Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ¹⁰Hospital Universitario de Toledo, Toledo, Spain, ¹¹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹²HOSPITAL GENERAL UNIVERSITARIO VALENCIA SPAIN, Ontinyent, Comunidad Valenciana, Spain, ¹³Hospital Universitario Infanta Sofía, Madrid, Madrid, Spain, ¹⁴Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda (Madrid), Spain, ¹⁵Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain, ¹⁶Hospital General Universitario Gregorio Marañón, Madrid, Spain, ¹⁷CHU Ourense, O Carballino, Spain, ¹⁸BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ¹⁹Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas, Spain, ²⁰Complejo Hospitalario Segovia, Segovia, Castilla y Leon, Spain, ²¹Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain, ²²National Health system, Alicante, Spain, ²³Hospital General de Valencia, Valencia, Comunidad Valenciana, Spain, ²⁴IBIMA, Málaga, Andalucia, Spain, ²⁵Hospital Perpetuo Socorro, Badajoz, Spain, ²⁶Hospital Universitario Montecelo, Pontevedra, Galicia, Spain, ²⁷Hospital de Merida, Merida, Extremadura, Spain, ²⁸Hospital General Universitario de Alicante, Alicante, Spain, ²⁹Hospital Universitario de la Princesa, Madrid, Spain, ³⁰Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory disease often associated with elevated serum IgG4 levels. High dose corticosteroids are the cornerstone of treatment, but…
Abstract Number: 2502 • ACR Convergence 2024
Characterization of the Tissue Fibroblast Repertoire in IgG4-Related Ophthalmic Disease
Eduardo Martin Nares, Gabriela Hernández-Molina, Diana Aguilar-León, Norma Ofelia Uribe-Uribe and Janette Furuzawa-Carballeda, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory condition characterized by tissue infiltration with IgG4+ plasma cells. Fibrosis in the target organs is one of…
Abstract Number: 0536 • ACR Convergence 2024
A Population Modeling and Simulation of the Effect of Obexelimab Exposure on the QTc Interval in Healthy Volunteers and Patients with Rheumatoid Arthritis or IgG4-Related Disease
Claire Mukashyaka¹, Xiaodong Wang¹, Sujata Arora¹, Mason Yamashita¹, Allen Poma¹ and Tanya Fischer², ¹Zenas BioPharma, Waltham, MA, ²Zenas BioPharma, Waltham, CA
Background/Purpose: Obexelimab is a novel bifunctional antibody that inhibits B cells, CD19-expressing plasma cells, and plasmablast activity and has the potential to provide clinical benefit…
Abstract Number: 2507 • ACR Convergence 2024
IgG4-related Disease Features and Immunological Profile in a Tertiary Center in Sao Paulo-Brazil
Frederico Pinheiro¹, Cristina Orikaza², Gerson Keppeke³, Emília Sato² and Alexandre de Souza⁴, ¹Universidade Federal de Sao Paulo - UNIFESP, São Paulo, SP, Brazil, ²Universidade Federal de Sao Paulo, São Paulo, SP, Brazil, ³Universidad Catolica del Norte, São Paulo, Coquimbo, Brazil, ⁴UNIFESP-EPM, São Paulo, SP, Brazil
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic, fibroinflammatory condition affecting almost all organs. It is a rare entity that is continuously being studied worldwide. It…
Abstract Number: 0736 • ACR Convergence 2024
Treatment of IgG4-Related Disease (IgG4-RD) with Elotuzumab, an Inhibitor of SLAM-F7: Report of a Phase 2 Clinical Trial
John Stone¹, Arezou Khosroshahi², Shounak Majumder³, Cory Perugino⁴, Ana Fernandes⁴, Grace McMahon⁴, Isha Jha⁴, John Varghese², Adriana Delgado³, Guy Katz⁴, Zachary Wallace⁵, Shiv Pillai⁴, William Barry⁶, Ashley Pinckney⁷, Ellen Goldmuntz⁸, Beverly Welch⁹ and Kaitlin McShea⁹, ¹Massachusetts General Hospital , Harvard Medical School, Concord, MA, ²Emory University, Atlanta, GA, ³Mayo Clinic, rochester, MN, ⁴Massachusetts General Hospital, Boston, MA, ⁵Massachusetts General Hospital, Newton, MA, ⁶Rho, Durham, NC, ⁷Rho, St Louis Park, NC, ⁸NIAID/ NIH, Washington, DC, ⁹Rho, Washington, DC
Background/Purpose: CD4+ cytotoxic T lymphocytes (CD4+ CTLs), plasmablasts, and selected other cells of the T and B cell lineages have been identified as cellular linchpins of…

1
2
3
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].